Commentaries
Vol. 4 No. 2 (2025)
Comments on “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 1 July 2025
1167
Views
400
Downloads
Authors
Quoting Jake Elwood, after reading the review by May et al., “we’ve seen the light.” Indeed, the term “anticoagulation stewardship” can serve as a programmatic manifesto for every scientific society dealing with hemostasis and thrombosis. The expression “antimicrobial stewardship” has become widely used and integrated into healthcare service planning, so why not start thinking in terms of “anticoagulation stewardship”?.....
Downloads
Download data is not yet available.
Citations
1. May JE, Allen AL, Samuelson Bannow BT, et al. Safe and effective anticoagulation use: case studies in anticoagulation stewardship. J Thromb Haemost 2025;23:779-89. DOI: https://doi.org/10.1016/j.jtha.2024.11.024
2. Budnitz DS, Shehab N, Lovegrove MC, et al. US emergency department visits attributed to medication harms, 2017-2019. JAMA 2021;326:1299-309. DOI: https://doi.org/10.1001/jama.2021.13844
3. Burnett AE, Barnes GD. A call to action for anticoagulation stewardship. Res Pract Thromb Haemost 2022;6:e12757. DOI: https://doi.org/10.1002/rth2.12757
4. Anticoagulation Forum. Core Elements of Anticoagulation Stewardship Programs. Newton, Anticoagulation Forum; 2019.
5. National Quality Forum. Advancing Anticoagulation Stewardship: A Playbook. Washington, DC, National Quality Forum; 2022.
6. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes 2016;9:182–5. DOI: https://doi.org/10.1161/CIRCOUTCOMES.115.002366
7. Sylvester KW, Chen A, Lewin A, et al. Optimization of DOAC management services in a centralized anticoagulation clinic. Res Pract Thromb Haemost 2022;6:e12696. DOI: https://doi.org/10.1002/rth2.12696
8. Samuelson Bannow B. Are outpatient anticoagulation management services the wave of the future (again)? Res Pract Thromb Haemost 2022;6:e12735. DOI: https://doi.org/10.1002/rth2.12735
9. Lee J, Lindsley J, Chasler J, et al. The impact of an antithrombotic stewardship program on heparin-induced thrombocytopenia management. J Pharm Pract 2023;36:1343-9. DOI: https://doi.org/10.1177/08971900221116185
10. Rudd K, Winans A, Triller D. Standardizing periprocedural anticoagulation management: a stewardship initiative. J Thromb Thrombolysis 2023;56:361-7. DOI: https://doi.org/10.1007/s11239-023-02854-2
11. Samuelson Bannow BT. Management of abnormal uterine bleeding on anticoagulation: the patient-clinician perspective. J Thromb Haemost 2024;22:1819-25. DOI: https://doi.org/10.1016/j.jtha.2024.04.002
12. National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: assessment and management. National Institute for Health and Care Excellence: Clinical Guidelines. London, NICE; 2021.
13. Silvari V, Crowley E, Carey M, et al. Value of hospital anticoagulation stewardship programme: a systematic review. Thromb Update 2024;14:100158. DOI: https://doi.org/10.1016/j.tru.2023.100158
14. McLintock C, Pabinger I, Bauer KA, et al. International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. J Thromb Haemost 2016;14:3-27. DOI: https://doi.org/10.1111/jth.13162
How to Cite
1.
Marietta M, Castaman G. Comments on “Safe and effective anticoagulation use: case studies in anticoagulation stewardship”. Bleeding Thromb Vascul Biol [Internet]. 2025 Jul. 1 [cited 2025 Sep. 18];4(2). Available from: https://www.btvb.org/btvb/article/view/180
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Paolo Simioni, Vittorio Pengo, Paolo Prandoni, Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Bianca Clerici, Mariangela Scavone, Gian Marco Podda, Recent advances in classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Giovanni Di Minno, Gaia Spadarella, Ilenia Lorenza Calcaterra, Giancarlo Castaman, Paolo Simioni, Raimondo De Cristofaro, Cristina Santoro, Flora Peyvandi, Matteo Di Minno, The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Ilaria Nichele, Giuseppe Carli, Alberto Tosetto, Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 1 (2024)
- Luca Puccetti, Vincenzo Sammartano, Federico Caroni, Margherita Malchiodi, Paola Calzoni, Eleonora Franceschini, Lucrezia Galasso, Monica Bocchia, Safety of COVID-19 mRNA vaccination in patients with history of acquired hemophilia A: a case series , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Stefano Lancellotti, Monica Sacco, Maira Tardugno, Antonietta Ferretti, Raimondo De Cristofaro, The von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Juan Eirís, Marina Suárez-Terrón, Pablo Granados, David Martínez-Campuzano, Ana Rosa Cid, Saturnino Haya, Santiago Bonanad, Allopurinol-induced acquired von Willebrand syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 4 (2023)
- Yishi Tan, Marc Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J. Stanworth, Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Samantha Pasca, Cristina Santoro, Chiara Ambaglio, Marisanta Napolitano, Marta Milan, Letizia Natali, Silvia Nannizzi, Filippo Mori, Paolo Simioni, Ezio Zanon, Comparison among three different bleeding scores and the thrombin generation assay to assess the different hemorrhagic phenotypes in patients with FVII deficiency , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
1-10 of 97
Next
You may also start an advanced similarity search for this article.
